Creo Medical Group (LON:CREO) Stock Price Up 2.5% - Here's What Happened

Key Points

• Creo Medical Group's stock price increased by 2.5% to GBX 13.46 ($0.18), with a total trading volume significantly lower than its average.
• The company reported a quarterly earnings loss of GBX (8) (($0.11)) per share and a negative net margin of 73.93%, forecasting further losses for the current fiscal year.
• Insider transactions revealed that Kevin Crofton purchased 701,750 shares at GBX 16 ($0.22), while Richard John Rees sold 6,429 shares at GBX 14 ($0.19).

Creo Medical Group PLC (LON:CREO - Get Free Report)'s stock price shot up 2.5% during mid-day trading on Thursday . The company traded as high as GBX 13.49 ($0.18) and last traded at GBX 13.46 ($0.18). 287,768 shares changed hands during trading, a decline of 75% from the average session volume of 1,143,067 shares. The stock had previously closed at GBX 13.13 ($0.18).

Creo Medical Group Stock Performance

The stock's 50-day simple moving average is GBX 13.35 and its 200-day simple moving average is GBX 13.28. The stock has a market cap of £55.59 million, a price-to-earnings ratio of -2.18 and a beta of 0.86. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.

Creo Medical Group (LON:CREO - Get Free Report) last announced its earnings results on Monday, May 19th. The company reported GBX (8) earnings per share (EPS) for the quarter. Creo Medical Group had a negative return on equity of 41.79% and a negative net margin of 73.93%. Analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Creo Medical Group news, insider Craig Jonathan Gulliford sold 6,429 shares of the stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of GBX 14, for a total transaction of £900.06. Also, insider Kevin Crofton purchased 701,750 shares of the business's stock in a transaction dated Friday, May 30th. The shares were purchased at an average cost of GBX 16 per share, with a total value of £112,280. Company insiders own 22.43% of the company's stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.